<?xml version="1.0" encoding="UTF-8"?>
<p id="Par67">Another influenza vaccine based on the use of flagellin to increase the immunogenicity of M2e [
 <xref ref-type="bibr" rid="CR46">46</xref>] was shown to be safe in a phase I clinical trial after intramuscular administration in doses of 0.3 and 1.0 μg. However, administration in doses of 3.0 μg or 10.0 μg was accompanied by undesirable symptoms (fever, diarrhea, fatigue, headache and muscle pain), although this vaccine demonstrated high immunogenicity (NCT00921206, VaxInnate) [
 <xref ref-type="bibr" rid="CR123">123</xref>]. The phase II trial of this vaccine ended in 2011 (NCT00921947, VaxInnate), but the test results are not yet available.
</p>
